Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases.
Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases. Opportunities are now available for the following:
For more info click here
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.